<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2016-06-01" updated="2020-01-02">
  <drugbank-id primary="true">DB11603</drugbank-id>
  <name>Human rabies virus immune globulin</name>
  <description>IMOGAM Rabies Pasteurized is indicated for post-exposure prophylaxis in persons suspected of exposure to rabies, who have not previously received a complete immunization regimen with a cell culture produced rabies vaccine.&#13;
&#13;
Persons previously vaccinated with other types of rabies vaccines in whom adequate antibody levels have not been demonstrated should receive full post-exposure prophylaxis with RIG and a cell culture-produced rabies vaccine.&#13;
&#13;
IMOGAM Rabies Pasteurized should be administered promptly after exposure, in conjunction with rabies vaccine. If IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies vaccine. Since rabies vaccine-induced antibody begins to appear within one week, there is no value in administering rabies immune globulin more than eight days after rabies vaccination has begun.&#13;
&#13;
Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory Committee on Immunization Practices (ACIP), and the World Health Organization (WHO).</description>
  <cas-number/>
  <unii>95F619ATQ2</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For use in prophylaxis against rabies virus in patients who have been exposed to the virus and are immunocompromised or have not previously recieved the rabies vaccine [FDA Label].</indication>
  <pharmacodynamics>Rabies immune globulin prevents viral invasion of the central nervous system.</pharmacodynamics>
  <mechanism-of-action>Rabies immune globulin binds the rabies virus, preventing it from invading the central nervous system [FDA Label]. This affords time for the rabies vaccine, which is also administered in cases of rabies exposure, to induce an immune response to destroy the virus. Rabies immunoglobulin should only be administered up to eight days after exposure as the host begins to produce sufficient antibodies to the virus one week after exposure. Repeat dosing should also be avoided as it may interfere with induction of immune response by the rabies vaccine.</mechanism-of-action>
  <toxicity>No toxicological studies have been performed. Isolated cases of angioneurotic edema, skin rash, nephrotic syndrome, and anaphylactic shock after injection have been noted [FDA Label].</toxicity>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Rabies immune globulin</synonym>
    <synonym language="english" coder="">Rabies immune globulin (human)</synonym>
    <synonym language="english" coder="">Rabies immune globulin human</synonym>
    <synonym language="english" coder="">Rabies immune globulin, human</synonym>
    <synonym language="english" coder="">Rabies immune globulin,human</synonym>
    <synonym language="english" coder="">Rabies immunoglobulin (human)</synonym>
    <synonym language="english" coder="">Rabies immunoglobulins</synonym>
  </synonyms>
  <products>
    <product>
      <name>Hyperab Rabies Immune Globulin Human</name>
      <labeller>Cutter Med &amp; Biol, Division Of Miles Canada Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00345733</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>1998-09-25</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>HyperRAB</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13533-318</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1974-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 [iU]/1mL</strength>
      <route>Infiltration; Intramuscular</route>
      <fda-application-number>BLA101144</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>HyperRAB</name>
      <labeller>Grifols Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02486571</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>300 unit</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hyperrab S/d</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13533-618</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>150 [iU]/1mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA101144</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hyperrab S/d</name>
      <labeller>Grifols Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230700</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>150 unit</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Imogam Rabies Inj 150unit/ml</name>
      <labeller>Pasteur m√ârieux Serums Et Vaccins, s.a.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01910477</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-12</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Imogam Rabies Pasteurized</name>
      <labeller>Sanofi Pasteur Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237328</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Imogam Rabies-HT</name>
      <labeller>Sanofi Pasteur Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49281-190</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 [iU]/1mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103932</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kamrab</name>
      <labeller>Kamada Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02482509</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kamrab</name>
      <labeller>Kamada Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02482436</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kedrab</name>
      <labeller>Kedrion Biopharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76125-150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 [iU]/1mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA125613</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>RabAvert</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02267667</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>2.5 IU/mL</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Kedrab</name>
      <ingredients>Human rabies virus immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>Hyperrab S/d</name>
      <ingredients>Human rabies virus immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>Imogam Rabies-HT</name>
      <ingredients>Human rabies virus immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>HyperRAB</name>
      <ingredients>Human rabies virus immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>Hyperrab S/d</name>
      <ingredients>Human rabies virus immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>Imogam Rabies Pasteurized</name>
      <ingredients>Human rabies virus immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>Imogam Rabies Inj 150unit/ml</name>
      <ingredients>Human rabies virus immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>Hyperab Rabies Immune Globulin Human</name>
      <ingredients>Human rabies virus immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>RabAvert</name>
      <ingredients>Human rabies virus immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>Kamrab</name>
      <ingredients>Human rabies virus immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>Kamrab</name>
      <ingredients>Human rabies virus immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>HyperRAB</name>
      <ingredients>Human rabies virus immune globulin</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Rabies Vaccines</category>
      <mesh-id>D011819</mesh-id>
    </category>
    <category>
      <category>Serum</category>
      <mesh-id>D044967</mesh-id>
    </category>
    <category>
      <category>Vaccines</category>
      <mesh-id>D014612</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Infiltration; Intramuscular</route>
      <strength>300 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular</route>
      <strength>300 unit</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intramuscular</route>
      <strength>150 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular</route>
      <strength>150 unit</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular</route>
      <strength>150 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular</route>
      <strength>2.5 IU/mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>80:04.00</ahfs-code>
    <ahfs-code>80:12.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00011</drugbank-id>
      <name>Interferon alfa-n1</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00018</drugbank-id>
      <name>Interferon alfa-n3</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfa-n3.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00033</drugbank-id>
      <name>Interferon gamma-1b</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon gamma-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00034</drugbank-id>
      <name>Interferon alfa-2a, Recombinant</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfa-2a, Recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Adalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Gemtuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pegaspargase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Infliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00068</drugbank-id>
      <name>Interferon beta-1b</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon beta-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00069</drugbank-id>
      <name>Interferon alfacon-1</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfacon-1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Trastuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Rituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00074</drugbank-id>
      <name>Basiliximab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Basiliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00075</drugbank-id>
      <name>Muromonab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Muromonab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tositumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Alemtuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00092</drugbank-id>
      <name>Alefacept</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Alefacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00095</drugbank-id>
      <name>Efalizumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Efalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00098</drugbank-id>
      <name>Antithymocyte immunoglobulin (rabbit)</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon alfa-2b</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00108</drugbank-id>
      <name>Natalizumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Natalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00111</drugbank-id>
      <name>Daclizumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Daclizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bevacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00120</drugbank-id>
      <name>Phenylalanine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Phenylalanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Carmustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Amsacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bleomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Chlorambucil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00293</drugbank-id>
      <name>Raltitrexed</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Raltitrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mitomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bexarotene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00309</drugbank-id>
      <name>Vindesine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Vindesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Floxuridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00352</drugbank-id>
      <name>Tioguanine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tioguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00380</drugbank-id>
      <name>Dexrazoxane</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dexrazoxane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Streptozocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Trifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Gemcitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Teniposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Epirubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00446</drugbank-id>
      <name>Chloramphenicol</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Chloramphenicol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Lenalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00488</drugbank-id>
      <name>Altretamine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Altretamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Zidovudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cisplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Oxaliplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Vincristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Propylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pentostatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Methotrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Linezolid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Clofarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pemetrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mycophenolate mofetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Daunorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Etoposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dacarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Temozolomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Penicillamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tacrolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Sirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00888</drugbank-id>
      <name>Mechlorethamine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mechlorethamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Azacitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Carboplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dactinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Azathioprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Doxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydroxyurea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01008</drugbank-id>
      <name>Busulfan</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Busulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mycophenolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Topotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mercaptopurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Melphalan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01073</drugbank-id>
      <name>Fludarabine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fludarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Leflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Flucytosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Capecitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Procarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Idarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ifosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Estramustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mitoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Lomustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dasatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01257</drugbank-id>
      <name>Eculizumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Eculizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01262</drugbank-id>
      <name>Decitabine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Decitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01280</drugbank-id>
      <name>Nelarabine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Nelarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Colchicine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01423</drugbank-id>
      <name>Stepronin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Stepronin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydroxychloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Castanospermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02806</drugbank-id>
      <name>2-Methoxyethanol</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with 2-Methoxyethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03523</drugbank-id>
      <name>Brequinar</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Brequinar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04572</drugbank-id>
      <name>Thiotepa</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Thiotepa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04845</drugbank-id>
      <name>Ixabepilone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ixabepilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pirfenidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Afelimomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Belinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05258</drugbank-id>
      <name>Interferon alfa</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05259</drugbank-id>
      <name>Glatiramer</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Glatiramer.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05260</drugbank-id>
      <name>Gallium nitrate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Gallium nitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05459</drugbank-id>
      <name>Briakinumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Briakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05472</drugbank-id>
      <name>omega interferon</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with omega interferon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06612</drugbank-id>
      <name>Mepolizumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mepolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06643</drugbank-id>
      <name>Denosumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Denosumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06662</drugbank-id>
      <name>Abetimus</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Abetimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06681</drugbank-id>
      <name>Belatacept</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Belatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bendamustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cabazitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pralatrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08059</drugbank-id>
      <name>Wortmannin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Wortmannin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fingolimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Brentuximab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Eribulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ruxolitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Teriflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Carfilzomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08895</drugbank-id>
      <name>Tofacitinib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tofacitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08908</drugbank-id>
      <name>Dimethyl fumarate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dimethyl fumarate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pomalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09033</drugbank-id>
      <name>Vedolizumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Vedolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tedizolid phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Blinatumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ibrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Palbociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Olaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Vilanterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Peginterferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09312</drugbank-id>
      <name>Antilymphocyte immunoglobulin (horse)</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11569</drugbank-id>
      <name>Ixekizumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ixekizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11580</drugbank-id>
      <name>Ravulizumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ravulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11616</drugbank-id>
      <name>Pirarubicin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pirarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11693</drugbank-id>
      <name>Voclosporin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Voclosporin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11708</drugbank-id>
      <name>Peficitinib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Peficitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11767</drugbank-id>
      <name>Sarilumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Sarilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11776</drugbank-id>
      <name>Brodalumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Brodalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11803</drugbank-id>
      <name>Sirukumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Sirukumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Baricitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11834</drugbank-id>
      <name>Guselkumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Guselkumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11988</drugbank-id>
      <name>Ocrelizumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ocrelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12025</drugbank-id>
      <name>Triptolide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Triptolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Siponimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12612</drugbank-id>
      <name>Ozanimod</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ozanimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mizoribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12692</drugbank-id>
      <name>Gusperimus</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Gusperimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cepeginterferon alfa-2B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12902</drugbank-id>
      <name>Trofosfamide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Trofosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12947</drugbank-id>
      <name>Doxifluridine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Doxifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12991</drugbank-id>
      <name>Deoxyspergualin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Deoxyspergualin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12996</drugbank-id>
      <name>Acteoside</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Acteoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13014</drugbank-id>
      <name>Hypericin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hypericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13068</drugbank-id>
      <name>9-(N-methyl-L-isoleucine)-cyclosporin A</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13241</drugbank-id>
      <name>Begelomab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Begelomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14219</drugbank-id>
      <name>Monomethyl fumarate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Monomethyl fumarate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14762</drugbank-id>
      <name>Risankizumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Risankizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14919</drugbank-id>
      <name>Rozanolixizumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Rozanolixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15253</drugbank-id>
      <name>Bleselumab</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bleselumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14039</drugbank-id>
      <name>Erenumab</name>
      <description>The risk or severity of adverse effects can be increased when Erenumab is combined with Human rabies virus immune globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The serum concentration of Theophylline can be increased when it is combined with Human rabies virus immune globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluocinolone acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluocortin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluperolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Formocortal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluclorolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00223</drugbank-id>
      <name>Diflorasone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Diflorasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00240</drugbank-id>
      <name>Alclometasone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Alclometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00253</drugbank-id>
      <name>Medrysone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Medrysone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00288</drugbank-id>
      <name>Amcinonide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Amcinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00324</drugbank-id>
      <name>Fluorometholone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluorometholone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00547</drugbank-id>
      <name>Desoximetasone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Desoximetasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00596</drugbank-id>
      <name>Ulobetasol</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ulobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00663</drugbank-id>
      <name>Flumethasone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Flumethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00838</drugbank-id>
      <name>Clocortolone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Clocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00846</drugbank-id>
      <name>Flurandrenolide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Flurandrenolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14596</drugbank-id>
      <name>Loteprednol etabonate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00896</drugbank-id>
      <name>Rimexolone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Rimexolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01013</drugbank-id>
      <name>Clobetasol propionate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Clobetasol propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01047</drugbank-id>
      <name>Fluocinonide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluocinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01130</drugbank-id>
      <name>Prednicarbate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Prednicarbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01260</drugbank-id>
      <name>Desonide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Desonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06781</drugbank-id>
      <name>Difluprednate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06786</drugbank-id>
      <name>Halcinonide</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Halcinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09095</drugbank-id>
      <name>Difluocortolone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Difluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13158</drugbank-id>
      <name>Clobetasone</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Clobetasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14540</drugbank-id>
      <name>Hydrocortisone butyrate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone butyrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14543</drugbank-id>
      <name>Hydrocortisone probutate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone probutate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14544</drugbank-id>
      <name>Hydrocortisone valerate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone valerate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Loteprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Prednisolone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Prednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluprednidene acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Methylprednisolone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Clocortolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Melengestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Betamethasone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15566</drugbank-id>
      <name>Prednisolone acetate</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Prednisolone acetate.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7918</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22955</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347911213</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0009755</id>
      <name>Rabies Virus Proteins</name>
      <organism>Rabies virus (strain Pasteur vaccins / PV)</organism>
      <actions>
        <action>antibody</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A184721</ref-id>
            <pubmed-id>4185138</pubmed-id>
            <citation>Sikes RK: Human rabies immune globulin. Public Health Rep. 1969 Sep;84(9):797-801.</citation>
          </article>
          <article>
            <ref-id>A184724</ref-id>
            <pubmed-id>30270905</pubmed-id>
            <citation>Franka R, Carson WC, Ellison JA, Taylor ST, Smith TG, Kuzmina NA, Kuzmin IV, Marissen WE, Rupprecht CE: In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3). pii: tropicalmed2030048. doi: 10.3390/tropicalmed2030048.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P08667" source="Swiss-Prot">
        <name>Glycoprotein</name>
        <general-function>Attaches the virus to host cellular receptor, inducing endocytosis of the virion. In the endosome, the acidic pH induces conformational changes in the glycoprotein trimer, which trigger fusion between virus and cell membrane. There is convincing in vitro evidence that the muscular form of the nicotinic acetylcholine receptor (nAChR), the neuronal cell adhesion molecule (NCAM), and the p75 neurotrophin receptor (p75NTR) bind glycoprotein and thereby facilitate rabies virus entry into cells (By similarity).</general-function>
        <specific-function/>
        <gene-name>G</gene-name>
        <locus/>
        <cellular-location>Virion membrane</cellular-location>
        <transmembrane-regions>460-480</transmembrane-regions>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi/>
        <molecular-weight>58534.885</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="103929">Rabies virus (strain Pasteur vaccins / PV)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08667</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GLYCO_RABVP</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052123|Glycoprotein
MVPQALLFVPLLVFPLCFGKFPIYTIPDKLGPWSPIDIHHLSCPNNLVVEDEGCTNLSGF
SYMELKVGYISAIKMNGFTCTGVVTEAETYTNFVGYVTTTFKRKHFRPTPDACRAAYNWK
MAGDPRYEESLHNPYPDYHWLRTVKTTKESLVIISPSVADLDPYDRSLHSRVFPGGNCSG
VAVSSTYCSTNHDYTIWMPENPRLGMSCDIFTNSRGKRASKGSETCGFVDERGLYKSLKG
ACKLKLCGVLGLRLMDGTWVAMQTSNETKWCPPGQLVNLHDFRSDEIEHLVVEELVKKRE
ECLDALESIMTTKSVSFRRLSHLRKLVPGFGKAYTIFNKTLMEADAHYKSVRTWNEIIPS
KGCLRVGGRCHPHVNGVFFNGIILGPDGNVLIPEMQSSLLQQHMELLVSSVIPLMHPLAD
PSTVFKNGDEAEDFVEVHLPDVHERISGVDLGLPNWGKYVLLSAGALTALMLIIFLMTCW
RRVNRSEPTQHNLRGTGREVSVTPQSGKIISSWESYKSGGETGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0052124|Glycoprotein (G)
ATGGTTCCTCAGGCTCTCCTGTTTGTACCCCTTCTGGTTTTTCCATTGTGTTTTGGGAAA
TTCCCTATTTACACGATACCAGACAAGCTTGGTCCCTGGAGCCCGATTGACATACATCAC
CTCAGCTGCCCAAACAATTTGGTAGTGGAGGACGAAGGATGCACCAACCTGTCAGGGTTC
TCCTACATGGAACTTAAAGTTGGATACATCTCAGCCATAAAAATGAACGGGTTCACTTGC
ACAGGCGTTGTGACGGAGGCTGAAACCTACACTAACTTCGTTGGTTATGTCACAACCACG
TTCAAAAGAAAGCATTTCCGCCCAACACCAGATGCATGTAGAGCCGCGTACAACTGGAAG
ATGGCCGGTGACCCCAGATATGAAGAGTCTCTACACAATCCGTACCCTGACTACCACTGG
CTTCGAACTGTAAAAACCACCAAGGAGTCTCTCGTTATCATATCTCCAAGTGTGGCAGAT
TTGGACCCATATGACAGATCCCTTCACTCGAGGGTCTTCCCTGGCGGGAATTGCTCAGGA
GTAGCGGTGTCTTCTACCTACTGCTCCACTAACCACGATTACACCATTTGGATGCCCGAG
AATCCGAGACTAGGGATGTCTTGTGACATTTTTACCAATAGTAGAGGGAAGAGAGCATCC
AAAGGGAGTGAGACTTGCGGCTTTGTAGATGAAAGAGGCCTATATAAGTCTTTAAAAGGA
GCATGCAAACTCAAGTTATGTGGAGTTCTAGGACTTAGACTTATGGATGGAACATGGGTC
GCGATGCAAACATCAAATGAAACCAAATGGTGCCCTCCCGGTCAGTTGGTGAATTTGCAC
GACTTTCGCTCAGACGAAATTGAGCACCTTGTTGTAGAGGAGTTGGTCAAGAAGAGAGAG
GAGTGTCTGGATGCACTAGAGTCCATCATGACCACCAAGTCAGTGAGTTTCAGACGTCTC
AGTCATTTAAGAAAACTTGTCCCTGGGTTTGGAAAAGCATATACCATATTCAACAAGACC
TTGATGGAAGCCGATGCTCACTACAAGTCAGTCAGAACTTGGAATGAGATCATCCCTTCA
AAAGGGTGTTTAAGAGTTGGGGGGAGGTGTCATCCTCATGTAAACGGGGTATTTTTCAAT
GGTATAATATTAGGACCTGACGGCAATGTCTTAATCCCAGAGATGCAATCATCCCTCCTC
CAGCAACATATGGAGTTGTTGGTATCCTCGGTTATCCCCCTTATGCACCCCCTGGCAGAC
CCGTCTACCGTTTTCAAGAACGGTGACGAGGCTGAGGATTTTGTTGAAGTTCACCTTCCC
GATGTGCACGAACGGATCTCAGGAGTTGACTTGGGTCTCCCGAACTGGGGGAAGTATGTA
TTACTGAGTGCAGGGGCCCTGACTGCCTTGATGTTGATAATTTTCCTGATGACATGCTGG
AGAAGAGTCAATCGATCGGAACCTACACAACACAATCTCAGAGGGACAGGGAGGGAGGTG
TCAGTCACTCCCCAAAGCGGGAAGATCATATCTTCATGGGAATCATACAAGAGCGGGGGT
GAGACCGGACTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00974</identifier>
            <name>Rhabdo_glycop</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>viral envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>virion membrane</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P11213" source="Swiss-Prot">
        <name>Large structural protein</name>
        <general-function>RNA-directed RNA polymerase that catalyzes the transcription of viral mRNAs, their capping and polyadenylation. The template is composed of the viral RNA tightly encapsidated by the nucleoprotein (N). The viral polymerase binds to the genomic RNA at the 3' leader promoter, and transcribes subsequently all viral mRNAs with a decreasing efficiency. The first gene is the most transcribed, and the last the least transcribed. The viral phosphoprotein acts as a processivity factor. Capping is concommitant with initiation of mRNA transcription. Indeed, a GDP polyribonucleotidyl transferase (PRNTase) adds the cap structure when the nascent RNA chain length has reached few nucleotides. Ribose 2'-O methylation of viral mRNA cap precedes and facilitates subsequent guanine-N-7 methylation, both acticities being carried by the viral polymerase. Polyadenylation of mRNAs occur by a stuttering mechanism at a slipery stop site present at the end viral genes. After finishing transcription of a mRNA, the polymerase can resume transcription of the downstream gene.</general-function>
        <specific-function>Atp binding</specific-function>
        <gene-name>L</gene-name>
        <locus/>
        <cellular-location>Virion</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>244484.195</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="103929">Rabies virus (strain Pasteur vaccins / PV)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11213</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>L_RABVP</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Protein L</synonym>
          <synonym>Replicase</synonym>
          <synonym>Transcriptase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052121|Large structural protein
MLDPGEVYDDPIDPIELEAEPRGTPTVPNILRNSDYNLNSPLIEDPARLMLEWLKTGNRP
YRMTLTDNCSRSFRVLKDYFKKVDLGSLKVGGMAAQSMISLWLYGAHSESNRSRRCITDL
AHFYSKSSPIEKLLNLTLGNRGLRIPPEGVLSCLERVDYDNAFGRYLANTYSSYLFFHVI
TLYMNALDWDEEKTILALWKDLTSVDIGKDLVKFKDQIWGLLIVTKDFVYSQSSNCLFDR
NYTLMLKDLFLSRFNSLMVLLSPPEPRYSDDLISQLCQLYIAGDQVLSMCGNSGYEVIKI
LEPYVVNSLVQRAEKFRPLIHSLGDFPVFIKDKVSQLEETFGSCARRFFRALDQFDNIHD
LVFVYGCYRHWGHPYIDYRKGLSKLYDQVHIKKVIDKSYQECLASDLARRILRWGFDKYS
KWYLDSRFLARDHPLTPYIKTQTWPPKHIVDLVGDTWHKLPITQIFEIPESMDPSEILDD
KSHSFTRTRLASWLSENRGGPVPSEKVIITALSKPPVNPREFLKSIDLGGLPDEDLIIGL
KPKERELKIEGRFFALMSWNLRLYFVITEKLLANYILPLFDALTMTDNLNKVFKKLIDRV
TGQGLLDYSRVTYAFHLDYEKWNNHQRLESTEDVFSVLDQVFGLKRVFSRTHEFFQKSWI
YYSDRSDLIGLREDQIYCLDASNGPTCWNGQDGGLEGLRQKGWSLVSLLMIDRESQIRNT
RTKVLAQGDNQVLCPTYMLSPGLSQEGLLYELESISRNAFSIYRAVEEGASKLGLIIKKE
ETMCSYDFLIYGKTPLFRGNILVPESKRWARVSCVSNDQIVNLANIMSTVSTNALTVAQH
SQSLIKPMRDFLLMSVQAVFHYLLFSPILKGRVYKILSAEGESFLLAMSRIIYLDPSLGG
VSGMSLGRFHIRQFSDPVSEGLSFWREIWLSSHESWIHALCQEAGNPDLGERTLESFTRL
LEDPTTLNIRGGASPTILLKDAIRKALYDEVDKVENSEFREAILLSKTHRDNFILFLTSV
EPLFPRFLSELFSSSFLGIPESIIGLIQNSRTIRRQFRKSLSKTLEESFYNSEIHGISRM
TQTPQRVGGVWPCSSERADLLREISWGRKVVGTTVPHPSEMLGLLPKSSISCTCGATGGG
NPRVSVSVLPSFDQSFFCTGPLKGYLGSSTSMSTQLFHAWEKVTNVHVVKRALSLKESIN
WFITRDSNLAQTLIRNIVSLTGPDFPLEEAPVFKRTGSALHRFKSARYSEGGYSSVCPNL
LSHISVSTDTMSDLTQDGKNYDFMFQPLMLYAQTWTSELVQRDTRLRDSTFHWHLQCNRC
VRPIDDVTLETSQIFEFPDVSKRISRMVSGAVPHFQRLPDIRLRPGDFESLSGREKSHHI
GSAQGLLYSILVAIHDSGYNDGTIFPVNIYGKVSPRDYLRGLARGVLIGSSICFLTRMTN
ININRPLELISGVISYILLRLDNHPSLYIMLREPSFREEIFSIPQKIPAAYPTTMKEGNR
SILCYLQHVLRYEREVITASPENDWLWIFSDFRSAKMTYLTLITYQSHLLLQRVERNLSK
SMRDNLRQLSSLMRQVLGGHGEDTLESDDNIQRLLKDSLRRTRWVDQEVRHAARTMTGDY
SPNKKVSRKVGCSEWVCSAQQVAVSTSANPAPVSELDIRALSKRFQNPLISGLRVVQWAT
GAHYKLKPILDDLNVFPSLCLVVGDGSGGISRAVLNMFPDAKLVFNSLLEVNDLMASGTH
PLPPSAIMRGGNDIVSRVIDFDSIWEKPSDLRNLATWKYFQSVQKQVNMSYDLIICDAEV
TDIASINRITLLMSDFALSIDGPLYLVFKTYGTMLVNPNYKAIQHLSRAFPSVTGFITQV
TSSFSSELYLRFSKRGKFFRDAEYLTSSTLREMSLVLFNCSSPKSEMQRARSLNYQDLVR
GFPEEIISNPYNEMIITLIDSDVESFLVHKMVDDLELQRGTLSKVAIIIAIMIVFSNRVF
NVSKPLTDPLFYPPSDPKILRHFNICCSTMMYLSTALGDVPSFARLHDLYNRPITYYFRK
QVILGNVYLSWSWSNDTSVFKRVACNSSLSLSSHWIRLIYKIVKTTRLVGSIKDLSGEVE
RHLHRYNRWITLENIRSRSSLLDYSCLCIGYSWKPAHAKTLV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0052122|Large structural protein (L)
ATGCTCGATCCTGGAGAGGTCTATGATGACCCTATTGACCCAATCGAGTTAGAGGCTGAA
CCCAGAGGAACCCCCACTGTCCCCAACATCTTGAGGAACTCTGACTACAATCTCAACTCT
CCTTTGATAGAAGATCCTGCTAGACTAATGTTAGAATGGTTAAAAACAGGGAATAGACCT
TATCGGATGACTCTAACAGACAATTGCTCCAGGTCTTTCAGAGTTTTGAAAGATTATTTC
AAGAAGGTAGATTTGGGTTCCCTCAAGGTGGGCGGAATGGCTGCACAGTCAATGATTTCT
CTCTGGTTATATGGTGCCCACTCTGAATCCAACAGGAGCCGGAGATGTATAACAGACTTG
GCCCATTTCTATTCCAAGTCGTCCCCCATAGAGAAGCTGTTAAATCTCACGCTAGGAAAT
AGAGGGCTGAGAATCCCCCCAGAGGGAGTGTTAAGTTGCCTTGAGAGGGTTGATTATGAT
AATGCATTTGGAAGGTATCTTGCCAACACGTATTCCTCTTACTTGTTCTTCCATGTAATC
ACCTTATACATGAACGCCCTAGACTGGGATGAAGAAAAGACCATCCTAGCATTATGGAAA
GATTTAACCTCAGTGGACATCGGGAAGGACTTGGTAAAGTTCAAAGACCAAATATGGGGA
CTGCTGATCGTGACAAAGGACTTTGTTTACTCCCAAAGTTCCAATTGTCTTTTTGACAGA
AACTACACACTTATGCTAAAAGATCTTTTCTTGTCTCGCTTCAACTCCTTAATGGTCTTA
CTTTCTCCCCCAGAGCCCCGATACTCAGATGACTTGATATCTCAGCTATGCCAGCTGTAC
ATTGCTGGGGATCAAGTCTTGTCTATGTGTGGAAACTCCGGCTATGAAGTCATCAAAATA
TTGGAGCCATATGTCGTGAATAGTTTAGTCCAGAGAGCAGAAAAGTTTAGGCCTCTCATT
CATTCCTTGGGAGACTTTCCTGTATTTATAAAAGACAAGGTAAGTCAACTCGAAGAGACG
TTCGGTTCCTGTGCAAGAAGGTTCTTTAGGGCTCTGGATCAATTCGACAACATACATGAC
TTGGTTTTTGTGTATGGCTGTTACAGGCATTGGGGGCACCCATATATAGATTATCGAAAG
GGTCTGTCAAAACTATATGATCAGGTTCACATTAAAAAAGTGATAGATAAGTCCTACCAG
GAGTGCTTAGCAAGCGACCTAGCCAGGAGGATCCTTAGATGGGGTTTTGATAAGTACTCC
AAGTGGTATCTGGATTCACGATTCCTAGCCCGAGACCACCCCTTGACTCCTTATATCAAA
ACCCAAACATGGCCACCCAAACATATTGTAGATTTGGTGGGGGATACATGGCACAAGCTC
CCGATCACGCAAATCTTTGAGATTCCTGAATCAATGGATCCATCAGAAATATTGGATGAC
AAATCACATTCTTTCACCAGAACGAGACTAGCTTCTTGGCTGTCAGAAAACCGAGGGGGG
CCTGTTCCTAGCGAAAAAGTTATTATCACGGCCCTGTCTAAGCCGCCTGTCAATCCCCGA
GAGTTTCTGAAGTCTATAGACCTCGGAGGATTGCCAGATGAAGACTTGATAATTGGCCTC
AAGCCAAAGGAACGGGAATTGAAGATTGAAGGTCGATTCTTTGCTCTAATGTCATGGAAT
CTAAGATTGTATTTTGTCATCACTGAAAAACTCTTGGCCAACTACATCTTGCCACTTTTT
GACGCGCTGACTATGACAGACAACCTGAACAAGGTGTTTAAAAAGCTGATCGACAGGGTC
ACCGGGCAAGGGCTTCTGGACTATTCAAGGGTCACATATGCATTTCACCTGGACTATGAA
AAGTGGAACAACCATCAAAGATTAGAGTCAACAGAGGATGTATTTTCTGTCCTAGATCAA
GTGTTTGGATTGAAGAGAGTGTTTTCTAGAACACACGAGTTTTTTCAGAAGTCCTGGATC
TATTATTCAGACAGATCAGACCTCATCGGGTTACGGGAGGATCAAATATACTGCTTAGAT
GCGTCCAACGGCCCAACCTGTTGGAATGGCCAGGATGGCGGGCTAGAAGGCTTACGGCAG
AAGGGCTGGAGTCTAGTCAGCTTATTGATGATAGATAGAGAATCTCAAATCAGGAACACA
AGAACCAAAGTACTAGCTCAAGGAGACAACCAGGTTTTATGTCCGACATATATGTTGTCG
CCAGGGCTATCTCAAGAGGGGCTCCTCTATGAATTGGAGAGCATATCAAGGAATGCATTT
TCGATATACAGAGCCGTCGAGGAAGGGGCATCTAAACTAGGGCTGATCATCAAGAAAGAA
GAGACCATGTGTAGTTATGACTTCCTCATCTATGGAAAAACCCCTTTGTTTAGAGGTAAC
ATATTGGTGCCTGAGTCCAAAAGATGGGCCAGAGTCTCTTGCGTCTCTAATGACCAAATA
GTCAACCTCGCCAATATAATGTCGACAGTGTCCACCAACGCGCTAACAGTGGCACAACAC
TCTCAATCTTTGATCAAACCGATGAGGGATTTTCTGCTCATGTCAGTACAGGCAGTCTTT
CACTACCTGCTATTTAGCCCAATCTTAAAGGGAAGAGTTTACAAGATTCTGAGCGCTGAA
GGGGAGAGCTTTCTCCTAGCCATGTCAAGGATAATCTATCTAGATCCTTCTTTGGGAGGG
GTATCTGGAATGTCCCTCGGAAGATTCCATATACGACAGTTCTCAGACCCTGTCTCTGAA
GGGTTATCCTTCTGGAGAGAGATCTGGTTAAGCTCCCACGAGTCCTGGATTCACGCGTTG
TGTCAAGAGGCTGGAAACCCAGATCTTGGAGAGAGAACACTCGAGAGCTTCACTCGCCTT
CTAGAAGATCCTACCACCTTAAATATCAGAGGAGGGGCCAGTCCTACCATTCTACTCAAG
GATGCAATCAGAAAGGCTTTATATGACGAGGTGGACAAGGTGGAGAACTCAGAGTTTCGA
GAGGCAATCCTGTTGTCCAAGACCCATAGAGATAATTTTATACTCTTCTTAACATCTGTT
GAGCCTCTGTTTCCTCGATTTCTCAGTGAGCTATTCAGTTCGTCTTTTTTGGGAATCCCC
GAGTCAATCATTGGACTGATACAAAACTCCCGAACGATAAGAAGGCAGTTTAGAAAGAGT
CTCTCAAAAACTTTAGAAGAATCCTTCTACAACTCAGAGATCCACGGGATTAGTCGGATG
ACCCAGACACCTCAGAGGGTTGGGGGGGTGTGGCCTTGCTCTTCAGAGAGGGCAGATCTA
CTTAGGGAGATCTCTTGGGGAAGAAAAGTGGTAGGCACGACAGTTCCTCACCCTTCTGAG
ATGTTGGGGTTACTTCCCAAGTCCTCTATTTCTTGCACTTGTGGAGCAACAGGAGGAGGC
AATCCTAGAGTTTCTGTATCAGTACTCCCGTCTTTTGATCAGTCATTTTTTTGCACGGGG
CCCCTAAAGGGGTACTTGGGCTCGTCCACCTCTATGTCGACCCAGCTATTCCATGCATGG
GAAAAAGTCACTAATGTTCATGTGGTGAAGAGAGCTCTATCGTTAAAAGAATCTATAAAC
TGGTTCATTACTAGAGATTCCAACTTGGCTCAAACTCTAATTAGGAACATTGTGTCTCTG
ACAGGCCCTGATTTCCCTCTAGAGGAGGCCCCTGTTTTCAAAAGGACGGGGTCAGCCTTG
CATAGGTTCAAGTCTGCCAGATACAGCGAAGGAGGGTATTCTTCTGTATGCCCGAACCTC
CTCTCTCATATTTCTGTTAGTACAGACACCATGTCTGATTTGACCCAAGACGGGAAGAAC
TACGATTTCATGTTCCAGCCATTGATGCTTTATGCACAGACATGGACATCAGAGCTGGTA
CAGAGAGACACAAGGCTAAGAGACTCTACGTTTCATTGGCACCTCCAATGCAACAGGTGT
GTGAGACCCATTGACGACGTGACCCTGGAGACCTCTCAGATCTTCGAGTTTCCGGATGTG
TCGAAAAGAATATCCAGAATGGTTTCTGGGGCTGTGCCTCACTTCCAGAGGCTTCCCGAT
ATCCGTCTGAGACCAGGAGATTTTGAATCTCTAAGCGGTAGAGAAAAGTCTCACCATATC
GGATCAGCTCAGGGGCTCTTATACTCAATCTTAGTGGCAATTCACGACTCAGGATACAAT
GATGGAACCATCTTCCCTGTCAACATATACGGCAAGGTTTCCCCTAGAGACTATTTGAGA
GGGCTCGCAAGGGGAGTATTGATAGGATCCTCGATTTGCTTCTTGACGAGAATGACAAAT
ATCAATATTAATAGACCTCTTGAATTGATCTCAGGGGTAATCTCATATATTCTCCTGAGG
CTAGATAACCATCCCTCCTTGTACATAATGCTCAGAGAACCGTCTTTTAGAGAAGAGATA
TTTTCTATCCCTCAGAAAATCCCCGCCGCTTATCCAACCACTATGAAAGAAGGCAACAGA
TCAATCTTGTGTTATCTCCAACATGTGCTACGCTATGAGCGAGAGGTAATCACGGCGTCT
CCAGAGAATGACTGGCTATGGATCTTTTCAGACTTTAGAAGTGCCAAAATGACGTACCTA
ACCCTCATTACTTACCAGTCTCATCTTCTACTCCAGAGGGTTGAGAGAAACCTATCTAAG
AGTATGAGAGATAACCTGCGACAATTGAGTTCCTTGATGAGGCAGGTGCTGGGCGGGCAC
GGAGAAGATACCTTAGAGTCAGACGACAACATTCAACGACTACTAAAAGACTCTTTACGA
AGGACAAGATGGGTGGATCAAGAGGTGCGCCATGCAGCTAGAACCATGACTGGAGATTAC
AGCCCCAACAAGAAGGTGTCCCGTAAGGTAGGATGTTCAGAATGGGTCTGCTCTGCTCAA
CAGGTTGCAGTCTCTACCTCAGCAAACCCGGCCCCTGTCTCGGAGCTTGACATAAGGGCC
CTCTCTAAGAGGTTCCAGAACCCTTTGATCTCGGGCTTGAGAGTGGTTCAGTGGGCAACC
GGTGCTCATTATAAGCTTAAGCCTATTCTAGATGATCTCAATGTTTTCCCATCTCTCTGC
CTTGTAGTTGGGGACGGGTCAGGGGGGATATCAAGGGCAGTCCTCAACATGTTTCCAGAT
GCCAAGCTTGTGTTCAACAGTCTTTTAGAGGTGAATGACCTGATGGCTTCCGGAACACAT
CCACTGCCTCCTTCAGCAATCATGAGGGGAGGAAATGATATCGTCTCCAGAGTGATAGAT
TTTGACTCAATCTGGGAAAAACCGTCCGACTTGAGAAACTTGGCTACCTGGAAATACTTC
CAGTCAGTCCAAAAGCAGGTCAACATGTCCTATGACCTCATTATTTGCGATGCAGAAGTT
ACTGACATTGCATCTATCAACCGGATAACCCTGTTAATGTCCGATTTTGCATTGTCTATA
GATGGACCACTCTATTTGGTCTTCAAAACTTATGGGACTATGCTAGTAAATCCAAACTAC
AAGGCTATTCAACACCTGTCAAGAGCGTTCCCCTCGGTCACAGGGTTTATCACCCAAGTA
ACTTCGTCTTTTTCATCTGAGCTCTACCTTCGATTCTCCAAACGAGGGAAGTTTTTCAGA
GATGCTGAGTACTTGACCTCTTCCACCCTTCGAGAAATGAGCCTTGTGTTATTCAATTGT
AGCAGCCCCAAGAGTGAGATGCAGAGAGCTCGTTCCTTGAACTATCAGGATCTTGTGAGA
GGATTTCCTGAAGAAATCATATCAAATCCTTACAATGAGATGATCATAACTCTGATTGAC
AGTGATGTAGAATCTTTTCTAGTCCACAAGATGGTGGATGATCTTGAGTTACAGAGGGGA
ACTCTGTCTAAAGTGGCTATCATTATAGCCATCATGATAGTTTTCTCCAACAGAGTCTTC
AACGTTTCCAAACCCCTAACTGACCCCTTGTTCTATCCACCGTCTGATCCCAAAATCCTG
AGGCACTTCAACATATGTTGCAGTACTATGATGTATCTATCTACTGCTTTAGGTGACGTC
CCTAGCTTCGCAAGACTTCACGACCTGTATAACAGACCTATAACTTATTACTTCAGAAAG
CAAGTCATTCTAGGGAACGTTTATCTATCTTGGAGTTGGTCCAACGACACCTCAGTGTTC
AAAAGGGTAGCCTGTAATTCTAGCCTGAGTCTGTCATCTCACTGGATCAGGTTGATTTAC
AAGATAGTGAAGACTACCAGACTCGTTGGCAGCATCAAGGATCTATCCGGAGAAGTGGAA
AGACACCTTCATAGGTACAACAGGTGGATCACCCTAGAGAATATCAGATCTAGATCATCC
CTACTAGACTACAGTTGCCTGTGCATCGGATACTCCTGGAAGCCTGCCCATGCTAAGACT
CTTGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00946</identifier>
            <name>Mononeg_RNA_pol</name>
          </pfam>
          <pfam>
            <identifier>PF14318</identifier>
            <name>Mononeg_mRNAcap</name>
          </pfam>
          <pfam>
            <identifier>PF14314</identifier>
            <name>Methyltrans_Mon</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>host cell cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>virion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>mRNA (guanine-N7-)-methyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA-directed 5'-3' RNA polymerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative stranded viral RNA replication</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P08671" source="Swiss-Prot">
        <name>Matrix protein</name>
        <general-function>Plays a major role in assembly and budding of virion. Completely covers the ribonucleoprotein coil and keep it in condensed bullet-shaped form. Inhibits viral transcription and stimulates replication. Plays a major role in early induction of TRAIL-mediated apoptosis in infected neurons (By similarity).</general-function>
        <specific-function>Structural constituent of virion</specific-function>
        <gene-name>M</gene-name>
        <locus/>
        <cellular-location>Virion membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>23157.225</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="103929">Rabies virus (strain Pasteur vaccins / PV)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08671</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MATRX_RABVP</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Phosphoprotein M2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052125|Matrix protein
MNFLRKIVKNCRDEDTQKPSPVSAPLDDDDLWLPPPEYVPLKELTSKKNRRNFCINGGVK
VCSPNGYSFGILRHILRSFDEIYSGNHRMVGLVKVVIGLALSGAPVPEGMNWVYKLRRTL
IFQWADSRGPLEGEELEYSQEITWDDNTEFVGLQIRVSAKQCHIRGRIWCINMNSRAGQL
WSDMSLQTQRSEEDKDSSLLLE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0052126|Matrix protein (M)
ATGAACTTTCTACGTAAGATAGTGAAAAATTGCAGGGACGAGGACACTCAAAAACCCTCT
CCCGTGTCAGCCCCTCTGGATGACGATGACTTGTGGCTTCCACCCCCTGAATACGTCCCG
CTAAAAGAACTTACAAGCAAGAAGAACAGGAGGAACTTTTGTATCAACGGAGGGGTTAAA
GTGTGTAGCCCGAATGGTTACTCGTTCGGGATCCTGCGGCACATTCTGAGATCATTCGAC
GAGATATATTCTGGGAATCATAGGATGGTCGGGTTAGTCAAAGTAGTTATTGGACTGGCT
TTGTCAGGAGCTCCAGTCCCTGAGGGCATGAACTGGGTATACAAGTTGAGGAGAACCCTT
ATCTTCCAGTGGGCTGATTCCAGGGGCCCTCTTGAAGGGGAGGAGTTGGAATACTCTCAG
GAGATCACTTGGGATGATAATACTGAGTTCGTCGGATTGCAAATAAGAGTGAGTGCAAAA
CAGTGTCATATCCGGGGCAGAATCTGGTGTATCAACATGAACTCGAGAGCAGGTCAACTA
TGGTCTGACATGTCTCTTCAGACACAAAGGTCCGAAGAGGACAAAGATTCCTCTCTGCTT
CTAGAATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF04785</identifier>
            <name>Rhabdo_M2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>host cell endomembrane system</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>viral envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>virion membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>structural constituent of virion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral budding via host ESCRT complex</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P06025" source="Swiss-Prot">
        <name>Nucleoprotein</name>
        <general-function>Encapsidates the genome in a ratio of one protein N per nine ribonucleotides, protecting it from nucleases. If expressed without protein P it binds non-specifically RNA and therefore can bind it's own mRNA. Interaction with protein P abolishes any non-specific RNA binding, and prevents phosphorylation. The soluble N-P complex encapsidates specifically the genomic RNA, with protein N protecting the genome like a pearl necklace. The encapsidated genomic RNA is termed the nucleocapsid (NC) and serves as template for viral transcription and replication. Protein N binds protein P in the NC through a different interaction, and can be phosphorylated. Subsequent viral replication is dependent on intracellular concentration of newly synthesized protein N. During replication, encapsidation by protein N is coupled to RNA synthesis and all replicative products are resistant to nucleases (By similarity).</general-function>
        <specific-function>Rna binding</specific-function>
        <gene-name>N</gene-name>
        <locus/>
        <cellular-location>Virion</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>50605.025</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="103929">Rabies virus (strain Pasteur vaccins / PV)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P06025</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NCAP_RABVP</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NP</synonym>
          <synonym>Nucleocapsid protein</synonym>
          <synonym>Protein N</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052119|Nucleoprotein
MDADKIVFKVNNQVVSLKPEIIVDQYEYKYPAIKDLKKPCITLGKAPDLNKAYKSVLSCM
SAAKLDPDDVCSYLAAAMQFFEGTCPEDWTSYGIVIARKGDKITPGSLVEIKRTDVEGNW
ALTGGMELTRDPTVPEHASLVGLLLSLYRLSKISGQSTGNYKTNIADRIEQIFETAPFVK
IVEHHTLMTTHKMCANWSTIPNFRFLAGTYDMFFSRIEHLYSAIRVGTVVTAYEDCSGLV
SFTGFIKQINLTAREAILYFFHKNFEEEIRRMFEPGQETAVPHSYFIHFRSLGLSGKSPY
SSNAVGHVFNLIHFVGCYMGQVRSLNATVIAACAPHEMSVLGGYLGEEFFGKGTFERRFF
RDEKELQEYEAAELTKTDVALADDGTVNSDDEDYFSGETRSPEAVYTRIIMNGGRLKRSH
IRRYVSVSSNHQARPNSFAEFLNKTYSSDS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0052120|Nucleoprotein (N)
ATGGATGCCGACAAGATTGTATTCAAAGTCAATAATCAGGTGGTCTCTTTGAAGCCTGAG
ATTATCGTGGATCAATATGAGTACAAGTACCCTGCCATCAAAGATTTGAAAAAGCCCTGT
ATAACTCTAGGAAAGGCTCCCGATTTAAATAAAGCATACAAGTCAGTTTTATCATGCATG
AGCGCCGCCAAACTTGATCCTGACGATGTATGTTCCTATTTGGCGGCGGCAATGCAGTTT
TTTGAGGGGACATGTCCGGAAGACTGGACCAGCTATGGAATCGTGATTGCACGAAAAGGA
GATAAGATCACCCCAGGTTCTCTGGTGGAGATAAAACGTACTGATGTAGAAGGGAATTGG
GCTCTGACAGGAGGCATGGAACTGACAAGAGACCCCACTGTCCCTGAGCATGCGTCCTTA
GTCGGTCTTCTCTTGAGTCTGTATAGGTTGAGCAAAATATCCGGGCAAAGCACTGGTAAC
TATAAGACAAACATTGCAGACAGGATAGAGCAGATTTTTGAGACAGCCCCTTTTGTTAAA
ATCGTGGAACACCATACTCTAATGACAACTCACAAAATGTGTGCTAATTGGAGTACTATA
CCAAACTTCAGATTTTTGGCCGGAACCTATGACATGTTTTTCTCCCGGATTGAGCATCTA
TATTCAGCAATCAGAGTGGGCACAGTTGTCACTGCTTATGAAGACTGTTCAGGACTGGTG
TCATTTACTGGGTTCATAAAACAAATCAATCTCACCGCTAGAGAGGCAATACTATATTTC
TTCCACAAGAACTTTGAGGAAGAGATAAGAAGAATGTTTGAGCCAGGGCAGGAGACAGCT
GTTCCTCACTCTTATTTCATCCACTTCCGTTCACTAGGCTTGAGTGGGAAATCTCCTTAT
TCATCAAATGCTGTTGGTCACGTGTTCAATCTCATTCACTTTGTAGGATGCTATATGGGT
CAAGTCAGATCCCTAAATGCAACGGTTATTGCTGCATGTGCTCCTCATGAAATGTCTGTT
CTAGGGGGCTATCTGGGAGAGGAATTCTTCGGGAAAGGGACATTTGAAAGAAGATTCTTC
AGAGATGAGAAAGAACTTCAAGAATACGAGGCGGCTGAACTGACAAAGACTGACGTAGCA
CTGGCAGATGATGGAACTGTCAACTCTGACGACGAGGACTACTTCTCAGGTGAAACCAGA
AGTCCGGAAGCTGTTTATACTCGAATCATAATGAATGGAGGTCGACTGAAGAGATCGCAC
ATACGGAGATATGTCTCAGTCAGTTCCAATCATCAAGCTCGTCCAAACTCATTCGCCGAG
TTTCTAAACAAGACATATTCGAGTGACTCATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00945</identifier>
            <name>Rhabdo_ncap</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>helical viral capsid</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>viral nucleocapsid</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA binding</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="P06747" source="Swiss-Prot">
        <name>Phosphoprotein</name>
        <general-function>Non catalytic polymerase cofactor and regulatory protein that plays a role in viral transcription and replication. Stabilizes the RNA polymerase L to the N-RNA template and binds the soluble protein N, preventing it from encapsidating non-genomic RNA. Also inhibits host IFN-alpha and IFN-beta signaling by binding and retaining phosphorylated STAT1 in the cytoplasm or by inhibiting the DNA binding of STAT1 in the nucleus. Might be involved, through interaction with host dynein, in intracellular microtubule-dependent virus transport of incoming virus from the synapse toward the cell body (By similarity).</general-function>
        <specific-function>Rna-directed 5'-3' rna polymerase activity</specific-function>
        <gene-name>P</gene-name>
        <locus/>
        <cellular-location>Virion</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>33165.98</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="103929">Rabies virus (strain Pasteur vaccins / PV)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P06747</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PHOSP_RABVP</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Protein M1</synonym>
          <synonym>Protein P</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052117|Phosphoprotein
MSKIFVNPSAIRAGLADLEMAEETVDLINRNIEDNQAHLQGEPIEVDNLPEDMGRLHLDD
GKSPNPGEMAKVGEGKYREDFQMDEGEDPSLLFQSYLDNVGVQIVRQIRSGERFLKIWSQ
TVEEIISYVAVNFPNPPGKSSEDKSTQTTGRELKKETTPTPSQRESQSSKARMAAQTASG
PPALEWSATNEEDDLSVEAEIAHQIAESFSKKYKFPSRSSGILLYNFEQLKMNLDDIVKE
AKNVPGVTRLARDGSKLPLRCVLGWVALANSKKFQLLVESNKLSKIMQDDLNRYTSC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0052118|Phosphoprotein (P)
ATGAGCAAGATCTTTGTCAATCCTAGTGCTATTAGAGCCGGTCTGGCCGATCTTGAGATG
GCTGAAGAAACTGTTGATCTGATCAATAGAAATATCGAAGACAATCAGGCTCATCTCCAA
GGGGAACCCATAGAAGTGGACAATCTCCCTGAGGATATGGGGCGACTTCACCTGGATGAT
GGAAAATCGCCCAACCCTGGTGAGATGGCCAAGGTGGGAGAAGGCAAGTATCGAGAGGAC
TTTCAGATGGATGAAGGAGAGGATCCTAGCCTCCTGTTCCAGTCATACCTGGACAATGTT
GGAGTCCAAATAGTCAGACAAATAAGGTCAGGAGAGAGATTTCTCAAGATATGGTCACAG
ACCGTAGAAGAGATTATATCCTATGTCGCGGTCAACTTTCCCAACCCTCCAGGAAAGTCT
TCAGAGGATAAATCAACCCAGACTACCGGCCGAGAGCTCAAGAAGGAGACAACACCCACT
CCTTCTCAGAGAGAAAGCCAATCCTCGAAAGCCAGGATGGCGGCTCAAACTGCTTCTGGC
CCTCCAGCCCTTGAATGGTCGGCCACCAATGAAGAGGATGATCTATCAGTGGAGGCTGAG
ATCGCTCACCAGATTGCAGAAAGTTTCTCCAAAAAATATAAGTTTCCCTCTCGATCCTCA
GGGATACTCTTGTATAATTTTGAGCAATTGAAAATGAACCTTGATGATATAGTTAAAGAG
GCAAAAAATGTACCAGGTGTGACCCGTTTAGCCCGTGACGGGTCCAAACTCCCCCTAAGA
TGTGTACTGGGATGGGTCGCCTTGGCCAACTCTAAGAAATTCCAGTTGTTAGTCGAATCC
AACAAGCTGAGTAAAATCATGCAAGATGACTTGAATCGCTATACATCTTGCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03012</identifier>
            <name>PP_M1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>host cell cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>virion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA-directed 5'-3' RNA polymerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>microtubule-dependent intracellular transport of viral material towards nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host STAT1 activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host STAT2 activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host type I interferon-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral entry into host cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral transcription</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>